WINDOW INTO THE BRAIN Commercial Objective is to Out-License

Our goal is to provide such a tool to enable breakthrough discoveries in research, drug development and patient care through single cell analysis. The most efficient approach to reach this research market is to out-license manufacturers the patented ZelosDx technology for incorporation into their blood testing assay systems. While this technology can be used across a broad set of instrument platforms, we believe there is a unique opportunity to bring this novel cellular approach to flow cytometry. 

This requires a source for the key reagents, i.e. antibodies, which are combined with other reagents into kits, and with appropriate assay development and instrumentation for an instrument reagent package. We are therefore seeking partners with expertise in the development of antibodies, reagents, as well as instruments for the application to flow cytometry. Given the number of potential biomarkers for the detection and monitoring of neuroinflammation, the ideal partner would already have antibodies for various brain-specific biomarkers or can easily develop or acquire them.